药物信息为NASACORT [na' za-cort] (triamcinolone acetonide) Nasal Inhaler (Aventis Pharmaceuticals, Inc.): DESCRIPTION
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- CLINICAL TRIALS
- INDIVIDUALIZATION OF DOSAGE
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- DOSAGE AND ADMINISTRATION
- OVERDOSAGE
- HOW SUPPLIED
- CONTENTS UNDER PRESSURE
- INFORMATION FOR THE PATIENT
- Diseases/Conditions Related to NASACORT [na' za-cort] (triamcinolone acetonide) Nasal Inhaler (Aventis Pharmaceuticals, Inc.)
- 外部链接相关的NASACORT [na' za-cort] (triamcinolone acetonide) Nasal Inhaler (Aventis Pharmaceuticals, Inc.)
Triamcinolone acetonide, USP, the active ingredient in Nasacort® Nasal Inhaler, is a glucocorticosteroid with a molecular weight of 434.5 and with the chemical designation 9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. (C24H31FO6).

Nasacort Nasal Inhaler is a metered-dose aerosol unit containing a microcrystalline suspension of triamcinolone acetonide in dichlorodifluoromethane and dehydrated alcohol USP 0.7% w/w. Each canister contains 15 mg triamcinolone acetonide. Each actuation delivers 55 mcg triamcinolone acetonide from the nasal actuator to the patient (estimated from in vitro testing). There are at least 100 actuations in one Nasacort Nasal Inhaler canister. After 100 actuations, the amount delivered per actuation may not be consistent and the unit should be discarded. Patients are provided with a check-off card to track usage as part of the Information for Patients tear-off sheet.
- Drug Information Provided by National Library of Medicine (NLM).
